Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Under the partnership, Alvotech will be responsible for commercial production at its new Reykjavik facility, where it will scale up and perform process validation.
Mark Levick, Alvotech’s chief executive officer, said in a statement that the partnership “marks an important milestone for our company as we work towards expanding our contract manufacturing business. We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
The deal is the latest in a string of agreements related to biosimilars for Prestige, which in July entered into an exclusive agreement with Pharmapark LLC to supply and commercialize Prestige’s trastuzumab biosimilar, HD201, in Russia.
The Pharmapark deal came on the heels of an agreement with Mundipharma to license and supply the same biosimilar in parts of Europe.
In 2018, Prestige announced entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets, and even earlier, Prestige inked a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
In May of this year, the European Medicines Agency accepted for review a Marketing Authorization Application for HD201, and the company is also developing biosimilars referencing bevacizumab, adalimumab, denosumab, aflibercept, eculizumab, and ipilimumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.